CYTK Cytokinetics Incorporated

Cytokinetics Announces Data From Two Presentations at the HFSA Virtual Annual Scientific Meeting 2020

Cytokinetics Announces Data From Two Presentations at the HFSA Virtual Annual Scientific Meeting 2020
EN
05/10/2020

Underlying

CYTKCytokinetics Incorporated

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Cytokinetics Incorporated

Free Trial
CYTK Cytokinetics I...

Cytokinetics Inc: 2 directors

Two Directors at Cytokinetics Inc sold after exercising options/sold 5,886 shares at between 61.210USD and 61.620USD. The significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the...

CYTK CYTOKINETICS INCORPORATED
9h / 48m 9h / 48m 1 EN
 PRESS RELEASE
Free
CYTK Cytokinetics I...

Cytokinetics to Participate in March Investor Conferences

Cytokinetics to Participate in March Investor Conferences SOUTH SAN FRANCISCO, Calif., March 02, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that members of the Company management team will participate in the following investor conferences in March: Leerink 2026 Global Healthcare Conference: Fireside chat on Monday, March 9, 2026 at 9:20 AM Eastern Time in Miami Beach, FL.Citizens 2026 Life Sciences Conference: Fireside chat on Tuesday, March 10, 2026 at 9:00 AM Eastern Time in Miami Beach, FL.2026 Jefferies Biotech on the Beach Summit: One-on-one m...

20h / 43m 1 EN
 PRESS RELEASE
Free
CYTK Cytokinetics I...

Cytokinetics Reports Fourth Quarter 2025 Financial Results and Provide...

Cytokinetics Reports Fourth Quarter 2025 Financial Results and Provides Business Update MYQORZO® Approved for Adults with Symptomatic Obstructive HCM in U.S., China and Europe; U.S. Launch Underway with First Prescriptions Dispensed within Days of Drug Availability Supplemental NDA for MAPLE-HCM Submitted to FDA in Q1 2026 Expect to Share Topline Results from ACACIA-HCM in Q2 2026 Company Provides 2026 Financial Guidance;~$1.2 Billion in Cash, Cash Equivalents and Investments as of December 31, 2025 SOUTH SAN FRANCISCO, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorpora...

February 24, 2026 1 EN
 PRESS RELEASE
Free
CYTK Cytokinetics I...

Cytokinetics Announces European Commission Approval of MYQORZO® (afica...

Cytokinetics Announces European Commission Approval of MYQORZO® (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy European Commission Approval Based on Results of SEQUOIA-HCM First European Launch Expected in Germany in Q2 2026 SOUTH SAN FRANCISCO, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the European Commission (EC) has approved MYQORZO® (aficamten), 5 mg, 10 mg, 15 mg and 20 mg tablets for the treatment of symptomatic (New York Heart Association, NYHA, class II-III) obstructi...

February 17, 2026 1 EN
 PRESS RELEASE
Free
CYTK Cytokinetics I...

Cytokinetics to Announce Fourth Quarter Results on February 24, 2026

Cytokinetics to Announce Fourth Quarter Results on February 24, 2026 SOUTH SAN FRANCISCO, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report fourth quarter results on February 24, 2026 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics’ senior management will host a conference call at 4:30 PM Eastern Time to discuss financial results and provide business updates. The conference call will be simultaneously webcast and can be accessed from the Investors & Media section of Cytokinetics’ website at...

February 12, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch